Sana Biotechnology, Inc. (SANA) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 41 days, typically, give or take 14 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026after close 36 8-K
Q2 FY2026Mon, Aug 10, 2026after close 41 8-K
Q1 FY2026Mon, May 11, 2026after close 41 8-K
Q4 FY2025Tue, Mar 3, 2026after close 62 8-K
Q3 FY2025Thu, Nov 6, 2025after close 37 8-K
Q2 FY2025Mon, Aug 11, 2025after close 42 8-K
Q1 FY2025Thu, May 8, 2025after close 38 8-K
Q4 FY2024Mon, Mar 17, 2025after close 76 8-K

What they guided beta

Q3 FY2026 "Exhibit 99.1 Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet cell transplantation with UP421 without immunosuppression in type 1 diabetes Advancing strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerati" exhibit
Q3 FY2026 "“We aim to share data from both of these programs in 2027 and anticipate both have the potential for relatively rapid proof of concept." exhibit
Q3 FY2026 "The $3.7 million decrease for the nine months ended September 30, 2026 compared to the same period in 2025 was primarily due to lower personnel-related expenses, including non-cash stock-based compensation, lower facility and other allocated costs, and third-party manufacturing costs at CDMOs associated with the suspended allogeneic CAR T programs incurred in the prior-year period that did not recur in 2026." exhibit
Q2 FY2026 "Exhibit 99.1 Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma and generating initial clinical data, including manufacturing and clinical trial readiness Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet" exhibit
Q2 FY2026 "14-month data from the study were presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting in July 2026, and additional data from the IST will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 on October 2." exhibit
Q2 FY2026 "Raised aggregate net proceeds of $93.3 million from sales of common stock through Sana’s at-the-market offering facility (ATM) and Mayo Clinic investment in the second quarter; expected cash runway into mid-2027." exhibit
Q2 FY2026 "Raised net proceeds of $93.3 million in the second quarter from sales of common stock through Sana’s ATM and equity financing." exhibit
Q2 FY2026 "The increase of $0.9 million for the three months ended June 30, 2026 compared to the same period in 2025 was primarily due to increased research, laboratory, and clinical development costs for our SC451 and SG293 programs and increased third-party manufacturing costs at contract development and manufacturing organizations (CDMOs) for our SC451 and SG293 programs, partially offset by lower personnel and other facility and allocated costs." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SANA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SANA

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

SANA earnings date badge

HTML

<a href="https://veritasdata.dev/company/SANA/"><img src="https://veritasdata.dev/embed/SANA.svg" alt="SANA earnings date" width="240" height="56"></a>

Markdown

[![SANA earnings date](https://veritasdata.dev/embed/SANA.svg)](https://veritasdata.dev/company/SANA/)

Script

<script async src="https://veritasdata.dev/embed/SANA.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SANA"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.